重要提醒！！！为防失联，请"星标"我们！进入无冕财经公众号，点击右上角"..."，再" "，以便您及时接收每篇推送~ wumiancaijing.com 最热的泛财经新闻，都在这儿了。 2月12日，广药集团纪律检查委员会发布文件，集中通报去年17起严重违纪违法典型案例，其中包括此前备受关注的广药集团腐败"窝案"。 文件通报的17起要案中，涉及广药集团旗下中一药业、王老吉药业、白云山制药总厂、何济公制药厂等多家核心子公司，涉案人职位上到董事长、总经 理、副总经理、部门总监、经理等各级管理人员，下至保卫科科长。腐败行为集中在药品原材料及包装材料采购、药品代理经销、广告投放与业务承揽、 款项结算、职务晋升等关键领域，部分人员还存在依托他人职权谋取私利、销售假药等严重违法行为，涉案总金额超2亿元。 ▲图片来自网络。 资讯整理：小冕 编辑：陈涧 设计：岚昇 广药集团腐败窝案15人被判刑 涉案超2亿，李楚源处理结果未出 本文由无冕财经（wumiancaijing）整理发布 从已披露的结果看，已有15人因受贿罪或销售假药罪被判处有期徒刑。其中，王老吉药业是被点名频次最高的企业，违法违纪行为涉及广药集团和王老吉 药业广告与媒 ...

Core Viewpoint - Fosun Pharma's subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has had its drug registration application for Cisplatin Injection accepted by the National Medical Products Administration, indicating progress in the development of this self-developed chemical drug for treating metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer [1]. Group 1 - The drug in question, Cisplatin Injection, is developed by the company and is intended for the treatment of specific types of cancer [1]. - The acceptance of the drug registration application marks a significant milestone for the company in expanding its oncology product portfolio [1].

经济观察网华昊中天医药-B(02563.HK)近期在资本运作、产品研发及法律事务方面取得多项进展。 股票近期走势 截至2026年2月13日，华昊中天医药-B(02563.HK)近期有以下值得关注的事件进展。 近期事件 关于公司全资附属US-Biostar认购的LFM Stable Income Fund SP基金投资款回收问题，开曼群岛法院已 于2025年12月3日批准委任接管人对该基金进行接管和清盘程序。资金回收进度可能对公司现金流产生 影响。 公司项目推进 公司已向上交所科创板递交上市申请材料，拟募资15亿元用于创新药研发及产业化项目。该进程的后续 审核结果将对公司资本路径产生重要影响。 以上内容基于公开资料整理，不构成投资建议。 公司首个创新药注射用亚胺西福预计将于2026年实现国内获批上市。此外，XNW5004、XNW27011及 XNW28012等3款药品已获CDE突破性治疗药物认定，预计在2027年至2028年间陆续上市。产品管线进 展是影响公司营收拐点的核心变量。 业绩经营情况 公司通过对外授权合作已实现累计协议交易金额超20亿美元，其中2025年收到1.30亿美元(税前)不可撤 销首付款，并预 ...

Core Viewpoint - The recent round of national drug procurement has resulted in 4,163 products from 1,020 companies being shortlisted, covering 316 commonly used drugs across 26 therapeutic areas, with only 21 original drugs winning bids, representing less than 10% of the total [1][2]. Group 1: Procurement Details - The procurement aims to reduce drug prices and patient burdens while reallocating saved healthcare funds to innovative drugs that provide significant clinical value [2]. - The procurement process was led by the medical insurance bureaus of Jiangsu, Henan, and Guangdong provinces, with a high selection rate of 93% among participating companies [2]. - The results of this procurement are expected to be implemented by the end of March 2026, with a procurement cycle lasting until the end of 2028 [2]. Group 2: Original Drug Participation - The original drugs selected include various formulations such as Fosinopril and Acarbose, with companies like Bristol-Myers Squibb and Sanofi involved [3]. - Several original drugs that had previously won bids in earlier rounds, such as Gefitinib and Clopidogrel, did not participate in this round, allowing generic competitors to dominate [4][3]. - The absence of original drugs in the procurement reflects a trend where original drugs face significant competition from generics post-patent expiration, leading to a decline in sales and profits [6]. Group 3: Market Dynamics - The "patent cliff" phenomenon has led to original drugs experiencing substantial sales and profit declines once their patents expire, which was previously mitigated by high prices and market share [6]. - Some original drug companies have reduced or dissolved their sales teams for products affected by procurement policies, yet many still find market opportunities outside public hospital settings [7]. - Cross-national pharmaceutical companies are increasingly focusing on innovative drug development while divesting mature product lines to local firms [8][9]. Group 4: Future Outlook - The Chinese government is implementing policies to support the development of innovative drugs, which is expected to expand the overall pharmaceutical market [10].

即将上任的葛丽鹤预计将面临来自投资者的巨大压力。由于过去几年赛诺菲的药物研发管线停滞不前， 加之美国反疫苗政策的影响，过去一年赛诺菲股价下跌超过25%。 当地时间2月12日，法国制药巨头赛诺菲宣布不再延长现任CEO韩保罗（Paul Hudson）的任期，并任命 65岁的现默克CEO、西班牙人葛丽鹤（Belén Garijo）为CEO。葛丽鹤也将成为赛诺菲史上首位女性 CEO，她将于2026年4月29日集团年度股东大会结束后正式履职。 不过在这一消息公布后，当天赛诺菲股价下跌4.5%。 一位医药行业高管对第一财经记者表示："赛诺菲的新任命让市场不解，这是公司股价下跌的原因，市 场可能期待一位更激进的管理者。" 葛丽鹤于2021年出任默克CEO，她还是法国化妆品巨头欧莱雅的董事会成员。去年，默克集团宣布，葛 丽鹤将按计划在2026年4月底完成任期。在加入默克前，葛丽鹤在赛诺菲工作了15年，当时她是欧洲和 加拿大制药业务副总裁兼执行委员会成员，主要工作包括整合赛诺菲在美国的罕见病药物部门。 不过葛丽鹤在默克任职期间，该公司在新药开发方面遭遇了许多挫折，仅三款新药进入市场。此外，尽 管她在不同领域有着广泛的经验，但市 ...

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received acceptance from the National Medical Products Administration for the drug registration application of Mivacurium Hydrochloride Injection, aimed at anesthesia induction and short-term surgical anesthesia [1] Group 1 - The new drug is classified as a Class 1 new drug for intravenous general anesthesia and was included in the "Major New Drug Creation" initiative in 2014 [1] - As of January 2026, the total R&D investment for this new drug is approximately 189 million yuan [1] - The projected sales for similar drugs in the domestic market in 2024 is around 4.238 billion yuan [1] Group 2 - Multiple approvals are required before the commercial production of the new drug, and the current acceptance does not have a significant impact on the company's performance at this stage [1]

Core Viewpoint - Recently, Fosun Pharma announced that its subsidiary, Fuhong Hanlin, received approval from the National Medical Products Administration to conduct Phase I clinical trials for HLX15-SC, a recombinant anti-CD38 fully human monoclonal antibody injection for the treatment of multiple myeloma [1] Group 1: Clinical Development - Fuhong Hanlin plans to conduct relevant clinical research for HLX15 in China once conditions are met [1] - HLX15 is a biosimilar to Daratumumab, with both subcutaneous (HLX15-SC) and intravenous (HLX15-IV) formulations intended for the treatment of multiple myeloma [1] Group 2: Financial Investment - As of January 2026, the company's cumulative R&D investment is approximately 192 million yuan [1] - According to the latest data, the global sales of Daratumumab formulations are expected to reach approximately 12.882 billion USD in 2024 [1]

Group 1 - The core viewpoint of the news is that Zhongheng Group (600252) anticipates a net profit loss of 250 million to 450 million yuan for the fiscal year 2025, primarily due to a decline in core business, impairment provisions, and losses from non-operating income [1] - The company’s subsidiary, Hunan Kangyuan Pharmaceutical Co., Ltd., received approval for a supplementary application for sodium lactate Ringer's injection, which may enhance its market competitiveness [1] Group 2 - On February 10, 2026, Zhongheng Group announced the absorption merger of its wholly-owned subsidiary Nanning Shuangqian by its holding subsidiary Shuangqian Industry, aimed at improving operational efficiency, reducing management costs, and optimizing resource allocation [2] - Following the merger, Nanning Shuangqian's legal status will be canceled, and its related assets and liabilities will be inherited by Shuangqian Industry, with no significant asset restructuring or payment required [2] Group 3 - Over the past week (February 7 to 13, 2026), Zhongheng Group's stock price has shown a downward trend, closing at 2.55 yuan on February 13, down 1.16% from 2.60 yuan on February 9, with a price fluctuation of 3.10% [3] - Trading volume peaked at 87.37 million yuan on February 12 but decreased to 52.19 million yuan on February 13, with a net inflow of 4.3975 million yuan on that day, indicating the stock is trading between a resistance level of 2.68 yuan and a support level of 2.52 yuan [3] - The overall performance of Zhongheng Group is weaker than the pharmaceutical and biotechnology sector, which saw a decline of 0.64% during the same period [3] Group 4 - Institutional interest in Zhongheng Group is low, with a neutral sentiment prevailing in the market; there have been no institutional surveys, and 100% of institutional ratings are neutral, with a fund holding ratio of only 0.01% [4] - Profit forecasts indicate an earnings per share of -0.11 yuan for 2024, reflecting a year-on-year decline of 547.14%, highlighting fundamental pressures on the company [4] - No recent targeted research reports have been published by brokerage firms regarding Zhongheng Group [4]

近7个交易日，福安药业股价震荡下行，累计跌幅1.12%，区间振幅4.20%。截至2月13日收盘，股价报 4.40元，当日持平，换手率0.50%，成交金额2135万元；主力资金呈净流出态势，2月12日单日净流出 1301.04万元，占成交额20.43%。技术面上，股价目前位于20日布林带下轨附近，MACD指标显示短期 趋势偏弱。同期医药生物板块下跌0.32%，公司股价表现略弱于行业平均水平。 经济观察网福安药业（300194）子公司共计28个药品品种在国家组织集采药品协议期满品种接续采购中 拟中选，涉及右美托咪定、阿哌沙班、喹硫平等品种，涵盖抗感染、精神类、麻醉类等领域。这些产品 2024年度合计销售额约6.80亿元，占公司营收28.43%；2025年前三季度合计销售额约3.29亿元，占营收 25.05%，采购周期至2028年12月31日。此次接续采购有助于稳定公司集采基本盘，但需关注价格下降 对毛利率的潜在压力。 股票近期走势 以上内容基于公开资料整理，不构成投资建议。 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) reported a revenue of 1.516 billion yuan for the fiscal year 2025, representing a year-on-year growth of 7.26%, and a net profit attributable to the parent company of 241 million yuan, which is an increase of 46.95% [1] Revenue Summary - The revenue growth during the reporting period was primarily driven by increased sales of formulation products, active pharmaceutical ingredients, intermediate products, and growth in technical service income [1] Profit Summary - The increase in net profit attributable to the parent company was significantly influenced by investment income [1] - However, the net profit attributable to the parent company after deducting non-recurring gains and losses declined due to the impact of stock incentive expenses; excluding these expenses, the adjusted net profit was 182 million yuan, reflecting a year-on-year increase of 31.57% [1]